294 related articles for article (PubMed ID: 24534107)
1. Eculizumab therapy.
Cataland SR
Biol Blood Marrow Transplant; 2014 Apr; 20(4):438-9. PubMed ID: 24534107
[No Abstract] [Full Text] [Related]
2. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
3. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
4. Drugs that inhibit complement.
Schrezenmeier H; Höchsmann B
Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
[TBL] [Abstract][Full Text] [Related]
5. Complement inhibitors are useful in secondary hemolytic uremic syndromes.
Caravaca-Fontan F; Praga M
Kidney Int; 2019 Oct; 96(4):826-829. PubMed ID: 31543153
[No Abstract] [Full Text] [Related]
6. A case of thrombotic micro-angiopathy after heart transplantation successfully treated with eculizumab.
Morales E; Rabasco C; Gutierrez E; Praga M
Transpl Int; 2015 Jul; 28(7):878-80. PubMed ID: 25712140
[No Abstract] [Full Text] [Related]
7. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
Wright RD; Bannerman F; Beresford MW; Oni L
BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
[TBL] [Abstract][Full Text] [Related]
8. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
9. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.
Schmidtko J; Peine S; El-Housseini Y; Pascual M; Meier P
Am J Kidney Dis; 2013 Feb; 61(2):289-99. PubMed ID: 23141475
[TBL] [Abstract][Full Text] [Related]
10. Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria.
Begum F; Khan N; Boisclair S; Malieckal DA; Chitty D
Am J Ther; 2023 May; 30(3):e209-e219. PubMed ID: 37104648
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
Risitano AM; Marotta S
Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients.
Genere L; Bacchetta J; Bertrand Y; Javouhey E; Cheikh N; Sellier-Leclerc AL
Arch Pediatr; 2018 Nov; 25(8):485-488. PubMed ID: 30340942
[TBL] [Abstract][Full Text] [Related]
13. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics.
Patriquin CJ; Kuo KHM
Transfus Med Rev; 2019 Oct; 33(4):256-265. PubMed ID: 31703946
[TBL] [Abstract][Full Text] [Related]
14. Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.
Araten DJ; Belmont HM; Schaefer-Cutillo J; Iyengar A; Mattoo A; Reddy R
Am J Case Rep; 2020 Sep; 21():e927418. PubMed ID: 32917848
[TBL] [Abstract][Full Text] [Related]
15. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
Fakhouri F; Frémeaux-Bacchi V; Loirat C
Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab deposits in vessel walls in thrombotic microangiopathy.
Cassol CA; Brodsky SV; Satoskar AA; Blissett AR; Cataland S; Nadasdy T
Kidney Int; 2019 Sep; 96(3):761-768. PubMed ID: 31345584
[TBL] [Abstract][Full Text] [Related]
17. Early initiation of eculizumab therapy for Streptococcus pneumoniae-associated hemolytic uremic syndrome.
See J; Bou Matar R; Baloglu O; Latifi SQ; Talati R; Agarwal HS
Pediatr Blood Cancer; 2021 Feb; 68(2):e28589. PubMed ID: 32672848
[No Abstract] [Full Text] [Related]
18. Thrombotic microangiopathy: eculizumab for atypical haemolytic uraemic syndrome: what next?
Fakhouri F; Frémeaux-Bacchi V
Nat Rev Nephrol; 2013 Sep; 9(9):495-6. PubMed ID: 23917793
[No Abstract] [Full Text] [Related]
19. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
20. Current and future pharmacologic complement inhibitors.
Risitano AM
Hematol Oncol Clin North Am; 2015 Jun; 29(3):561-82. PubMed ID: 26043392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
